Market Overview

With EU Approval For Puma Biotech's Breast Cancer Drug Unlikely, Cowen Downgrades

With EU Approval For Puma Biotech's Breast Cancer Drug Unlikely, Cowen Downgrades
8 Biggest Price Target Changes For Monday
52 Biggest Movers From Yesterday

Puma Biotechnology Inc (NASDAQ: PBYI) could face a setback in the launch of its breast cancer drug neratinib, as the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, relayed a "negative trend vote" after a meeting with the biotech company. 

The Analyst

Cowen analyst Chris Shibutani downgraded shares of Puma Biotech from Outperform to Market Perform and reduced the price target from $128 to $68.

The Thesis

The CHMP's communication suggests EU approval is unlikely and that additional steps need to be taken in order to obtain marketing approval in the EU, Shibutani said in a Wednesday note. (See the analyst's track record here.) 

Shibutani expects a negative outcome from the formal CHMP vote scheduled to take place in February, but said Puma Biotech could still appeal the decision. The likelihood of a reversal of a negative decision is low in the absence of a commitment to and/or production of data from an additional clinical trial, he said. 

Cowen does not project a similar negative outcome for the drug in the rest of the world, but remains cautious on the prospects, Shibutani said. 

The absence of EU approval will likely make the M&A narrative more challenging for Puma, the analyst said. Cowen has modeled an EU approval and was expecting the company to rope in a partner, with the former receiving royalties on sales, he said. 

Cowen is removing adjuvant sales outside the U.S. from its forecast, but leaving U.S. — including metastatic — projections intact.

The Price Action

Puma Biotech shares were up about 192 percent over the past year ahead of Tuesday's announcement. 

Shares were down 28.11 pecent at $65.35 at the time of publication Wednesday morning. 

Related Links:

Pharma M&A Picks Up Momentum

Attention Biotech Investors: Brace For These January PDUFA Events

Latest Ratings for PBYI

Nov 2018Goldman SachsUpgradesSellNeutral
Nov 2018JP MorganMaintainsUnderweightUnderweight
Nov 2018Cantor FitzgeraldMaintainsOverweightOverweight

View More Analyst Ratings for PBYI
View the Latest Analyst Ratings

Posted-In: breast cancerAnalyst Color Biotech Downgrades Price Target Top Stories Analyst Ratings General Best of Benzinga


Related Articles (PBYI)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

US New Homes News Generates A Trading Opportunity

Like Old Times: GE And Ford Step Onto Stage While Dollar Looks Back To 2014